Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma
BMJ Open ( IF 2.9 ) Pub Date : 2022-11-01 , DOI: 10.1136/bmjopen-2022-060983 Hanqing Zeng 1 , Chunjiang Wang 1 , Li-Ying Song 1 , Su-Jie Jia 1 , Xiaohui Zeng 2 , Qiao Liu 3
BMJ Open ( IF 2.9 ) Pub Date : 2022-11-01 , DOI: 10.1136/bmjopen-2022-060983 Hanqing Zeng 1 , Chunjiang Wang 1 , Li-Ying Song 1 , Su-Jie Jia 1 , Xiaohui Zeng 2 , Qiao Liu 3
Affiliation
Objective The perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin plus docetaxel (FLOT) was recommended by the Chinese Society of Clinical Oncology Guidelines for gastric cancer (2018 edition) for patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (class IIA). However, the economic impact of FLOT chemotherapy in China remains unclear. The analysis aimed to compare the cost-effectiveness of FLOT versus epirubicin, cisplatin plus fluorouracil or capecitabine (ECF/ECX) in patients with locally advanced resectable tumours. Design We developed a Markov model to compare the healthcare and economic outcomes of FLOT and ECF/ECX in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. Costs were estimated from the perspective of Chinese healthcare system. Clinical and utility inputs were derived from the FLOT4 phase II/III clinical trial and published literature. Sensitivity analyses were employed to assess the robustness of our result. The annual discount rate for costs and health outcomes was set at 5%. Outcome measures The primary outcome of incremental cost-effectiveness ratios (ICERs) was calculated as the cost per quality-adjusted life years (QALYs). Results The base-case analysis found that compared with ECF/ECX, the use of FLOT chemotherapy was associated with an additional 1.08 QALYs, resulting in an ICER of US$851/QALY. One-way sensitivity analysis results suggested that the HR of overall survival and progression-free survival had the greatest impact on the ICER. Probabilistic sensitivity analysis demonstrated that FLOT was more likely to be cost-effective compared with ECF/ECX at a willingness-to-pay threshold of US$31 513/QALY. Conclusions For patients with locally advanced resectable tumours, the FLOT chemotherapy is a cost-effective treatment option compared with ECF/ECX in China. Trial registration number [NCT01216644][1]. Data are available in a public, open access repository. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT01216644&atom=%2Fbmjopen%2F12%2F11%2Fe060983.atom
更新日期：2022-11-01
京公网安备 11010802027423号